Slow channel calcium inhibition blocks proinflammatory gene signaling and reduces macrophage responsiveness

Journal of Trauma

Volumn 52, Issue 3, 2002, Pages 434-442

  Cuschieri, Joseph ^a   Gourlay, David ^a   Garcia, Iris ^a   Jelacic, Sandra ^a   Maier, Ronald V ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium; Diltiazem; Endotoxin; Macrophage; Mitogen activated protein kinases; Tumor necrosis factor ; Verapamil

Indexed keywords

CALCIUM; CALCIUM ANTAGONIST; CALCIUM CHANNEL; CELL PROTEIN; DILTIAZEM; EGTAZIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; NUCLEAR PROTEIN; PROTEIN TYROSINE KINASE; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; VERAPAMIL;

ANIMAL CELL; CALCIUM SIGNALING; CHELATION; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; ESCHERICHIA COLI; GENE EXPRESSION; INFLAMMATION; MACROPHAGE; MALE; MEDIATOR RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RABBIT; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CALCIUM CHANNEL BLOCKERS; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FOCAL ADHESION KINASE 2; LIPOPOLYSACCHARIDES; MACROPHAGES, ALVEOLAR; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PROTEIN-TYROSINE KINASES; RABBITS; SEPSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA; VERAPAMIL;

EID: 0036119664     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005373-200203000-00004     Document Type: Article

References (58)

1. Wichmann MW, Inthorn D, Andress HJ, Schildberg FW. Incidence and mortality of severe sepsis in surgical intensive care patients: the influence of patient gender on disease process and outcome. Intensive Care Med. 2000; 26: 167-172.
2. Hardaway RM. A review of septic shock. Am Surg. 2000; 66: 22-29.
3. Venet C, Zeni F, Viallon A, et al. Endotoxaemia in patients with severe sepsis or septic shock. Intensive Care Med. 2000; 26: 538-544.
4. Turnage RH, Guice KS, Oldham KT. Pulmonary microvascular injury following intestinal reperfusion. New Horiz. 1994; 2: 463-475.
5. Brigham KL, Meyrick B. Endotoxin and lung injury. Am Rev Respir Dis. 1986; 133: 913-927.
6. Waage A, Brandtzaeg P, Espevik T, Halstensen A. Current understanding of the pathogenesis of gram-negative shock. Infect Dis Clin North Am. 1991; 5: 781-791.
7. Dinarello CA. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest. 1997; 112 (6 suppl):321S-329S.
8. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis. 2000; 181: 176-180.
9. Riche FC, Cholley BP, Pannis YH, et al. Inflammatory cytokine response in patients with septic shock secondary to generalized peritonitis. Crit Care Med. 2000; 28: 433-437.
10. Moller DR. Cells and cytokines involved in the pathogenesis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999; 16: 24-31.
11. Williams PA, Bohnsack JF, Augustine NH, Drummond WK, Rubens CE, Hill HR. Production of tumor necrosis factor by human cells in vitro and in vivo, induced by group b streptococci. J Pediatr. 1993; 123: 292-300.
12. Driscoll KE. Macrophage inflammatory proteins: biology and role in pulmonary inflammation. Exp Lung Res. 1994; 20: 473-490.
13. Pass HI, Mew D, Pass HA, Temeck BK. The macrophage, TNF, and other cytokines. Chest Surg Clin North Am. 1995; 5: 73-90.
14. Tran Van Nhieu J, Misset B, Lebargy F, Carlet J, Bernaudin JF. Expression of tumor necrosis factor-alpha gene in alveolar macrophages from patients with the adult respiratory distress syndrome. Am Rev Respir Dis. 1993; 147 (6 pt 1):1585-1589.
15. Goldfarb RD, Glock D, Johnson K, et al. Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock. Shock. 1998; 10: 258-264.
16. Yoshinari D, Takeyoshi I, Koibuchi Y, et al. Effects of a dual inhibitor of tumor necrosis factor-alpha and interleukin-1 on lipopolysaccharide-induced lung injury in rats: involvement of the p38 mitogen-activated protein kinase pathway. Crit Care Med. 2001; 29: 628-634.
17. Simpson AJ, Smith MD, Weverling GJ, et al. Prognostic value of cytokine concentrations (tumor necrosis factor-alpha, interleukin-6, and interleukin-10) and clinical parameters in severe melioidosis. J Infect Dis. 2000; 181: 621-625.
18. Spielmann S, Kerner T, Ahlers O, Keh D, Gerlach M, Gerlach H. Early detection of increased tumour necrosis factor alpha (TNFalpha) and soluble TNF receptor protein plasma levels after trauma reveals associations with the clinical course. Acta Anaesthesiol Scand. 2001; 45: 364-370.
19. Baldwin TJ, Ward W, Aitken A, Knutton S, Williams PH. Elevation of intracellular free calcium levels in HEP-2 cells infected with enteropathogenic Escherichia coli. Infect Immun. 1991; 59: 1599-1604.
20. Song SK, Karl IE, Ackerman JJ, Hotchkiss RS. Increased intracellular Ca2+: a critical link in the pathophysiology of sepsis? Proc Natl Acad Sci USA. 1993; 90: 3933-3937.
21. Bader MF, Taupenot L, Ulrich G, Aunis D, Ciesielski-Treska J. Bacterial endotoxin induces 'Ca2+;'i transients and changes the organization of actin in microglia. Glia. 1994; 11: 336-344.
22. Zaloga GP, Washburn D, Black KW, Prielipp R. Human sepsis increases lymphocyte intracellular calcium. Crit Care Med. 1993; 21: 196-202.
23. Bhattacharyya J, Sayeed MM. Alterations in intracellular calcium during sepsis. Indian J Physiol Pharmacol. 1997; 41: 344-352.
24. Hotchkiss RS, Karl IE. Calcium: a regulator of the inflammatory response in endotoxemia and sepsis. New Horiz. 1996; 4: 58-71.
25. Lo CJ, Garcia I, Cryer HG, Maier RV. Calcium and calmodulin regulate lipopolysaccharide-induced alveolar macrophage production of tumor necrosis factor and procoagulant activity. Arch Surg. 1996; 131: 44-50.
26. Fukuzawa M, Satoh J, Ohta S, et al. Modulation of tumor necrosis factor-alpha production with anti-hypertensive drugs. Immunopharmacology. 2000; 48: 65-74.
27. Matsumori A, Nunokawa Y, Sasayama S. Nifedipine inhibits activation of transcription factor NF-kappaB. Life Sci. 2000; 67: 2655-2661.
28. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983; 11: 1475-1489.
29. Slomiany BA, Kelly MM, Kurtz DT. Extraction of nuclear proteins with increased DNA binding activity. Biotechniques. 2000; 28: 938-942.
30. Deitch EA. Multiple organ failure: pathophysiology and potential future therapy. Ann Surg. 1992; 216: 117-134.
31. Beutler B, Cerami A. The biology of cachectin/TNF: a primary mediator of the host response. Annu Rev Immunol. 1989; 7: 625-655.
32. Michie HR, Spriggs DR, Manogue KR, et al. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery. 1988; 104: 280-286.
33. Szabo C, Hasko G, Nemeth ZH, Vizi ES. Calcium entry blockers increase interleukin-10 production in endotoxemia. Shock. 1997; 7: 304-307.
34. Nemeth ZH, Hasko G, Szabo C, Salzman AL, Vizi ES. Calcium channel blockers and dantrolene differentially regulate the production of interleukin-12 and interferon-gamma in endotoxemic mice. Brain Res Bull. 1998; 46: 257-261.
35. Geppert TD, Whitehurst CE, Thompson P, Beutler B. Lipopolysaccharide signals activation of tumor necrosis factor biosynthesis through the ras/raf-1/MEK/MAPK pathway. Mol Med. 1994; 1: 93-103.
36. Rutault K, Hazzalin CA, Mahadevan LC. Combinations of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-alpha (TNF-alpha) mRNA induction: evidence for selective destabilization of TNF-alpha transcripts. J Biol Chem. 2001; 276: 6666-6674.
37. Scherle PA, Jones EA, Favata MF, et al. Inhibition of MAP kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide-stimulated monocytes. J Immunol. 1998; 161: 5681-5686.
38. Blaukat A, Ivankovic-Dikic I, Gronroos E, et al. Adaptor proteins Grb2 and Crk couple Pyk2 with activation of specific mitogen-activated protein kinase cascades. J Biol Chem. 1999; 274: 14893-14901.
39. Li X, Hunter D, Morris J, Haskill JS, Earp HS. A calcium-dependent tyrosine kinase splice variant in human monocytes: activation by a two-stage process involving adherence and a subsequent intracellular signal. J Biol Chem. 1998; 273: 9361-9364.
40. Dikic I, Schlessinger J. Identification of a new Pyk2 isoform implicated in chemokine and antigen receptor signaling. J Biol Chem. 1998; 273: 14301-14308.
41. Williams LM, Ridley AJ. Lipopolysaccharide induces actin reorganization and tyrosine phosphorylation of Pyk2 and paxillin in monocytes and macrophages. J Immunol. 2000; 164: 2028-2036.
42. Jongeneel CV. Transcriptional regulation of the tumor necrosis factor alpha gene. Immunobiology. 1995; 193: 210-216.
43. Auron PE, Webb AC. Interleukin-1: a gene expression system regulated at multiple levels. Eur Cytokine Netw. 1994; 5: 573-592.
44. Liu R, O'Connell M, Johnson K, Pritzker K, Mackman N, Terkeltaub R. Extracellular signal-regulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappaB transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis Rheum. 2000; 43: 1145-1155.
45. Kristof AS, Marks-Konczalik J, Moss J. Mitogen-activated protein kinases mediate activator protein-1-dependent human inducible nitric-oxide synthase promoter activation. J Biol Chem. 2001; 276: 8445-8452.
46. Djavaheri-Mergny M, Dubertret L. UV-A-induced AP-1 activation requires the Raf/ERK pathway in human NCTC 2544 keratinocytes. Exp Dermatol. 2001; 10: 204-210.
47. Regenhard P, Goethe R, Phi-van L. Involvement of PKA, PKC, and Ca2+ in LPS-activated expression of the chicken lysozyme gene. J Leukoc Biol. 2001; 69: 651-658.
48. Newell CL, Deisseroth AB, Lopez-Berestein G. Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNF-alpha gene. J Leukoc Biol. 1994; 56: 27-35.
49. Spriggs DR, Deutsch S, Kufe DW. Genomic structure, induction, and production of TNF-alpha. Immunol Ser. 1992; 56: 3-34.
50. Walus KM, Fondacaro JD, Jacobson ED. Effects of calcium and its antagonists on the canine mesenteric circulation. Circ Res. 1981; 48: 692-700.
51. Braunwald E. Mechanism of action of calcium-channel-blocking agents. N Engl J Med. 1982; 307: 1618-1627.
52. Lee KS, Tsien RW. Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells. Nature. 1983; 302: 790-794.
53. Zucchi R, Limbruno U, Ronca-Testoni S, et al. Effects of verapamil, gallopamil, diltiazem and nifedipine on sarcoplasmic reticulum function in rat heart. Cardioscience. 1992; 3: 167-172.
54. Rosales C, Brown EJ. Calcium channel blockers nifedipine and diltiazem inhibit Ca2+ release from intracellular stores in neutrophils. J Biol Chem. 1992; 267: 1443-1448.
55. Letari O, Nicosia S, Chiavaroli C, Vacher P, Schlegel W. Activation by bacterial lipopolysaccharide causes changes in the cytosolic free calcium concentration in single peritoneal macrophages. J Immunol. 1991; 147: 980-983.
56. Bosson S, Kuenzig M, Schwartz SI. Increased survival with calcium antagonists in antibiotic-treated bacteremia. Circ Shock. 1986; 19: 69-74.
57. Lee HC, Lum BK. Protective action of calcium entry blockers in endotoxin shock. Circ Shock. 1986; 18: 193-203.
58. Hoyt DB, Junger WG, Loomis WH, Liu FC. Effects of trauma on immune cell function: impairment of intracellular calcium signaling. Shock. 1994; 2: 23-28.